Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (Avail Study)

NCT06465108 is registered in ClinicalTrials.gov with MBX Biosciences as lead sponsor.

NCT NCT06465108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (Avail Study)
Lead sponsor
MBX Biosciences
Phase
Phase 2
Overall status
Completed
Start date
August 8, 2024
Completion date
June 4, 2025
Enrollment
64 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism